SGHT - Sight Sciences Inc Trailing Twelve Months Revenue Growth

Sight Sciences, Inc. (SGHT) relies on stable demand within the defensive ophthalmology sector, where vision preservation remains a priority. The Omni technology creates a significant market barrier due to FDA patents. Simultaneously, the company is actively fighting for insurance coverage and market share. Year-over-year product sales dynamics for the TTM confirm fundamental stability, and the value of 16.00 expresses the metric level.
sightsciences.com (SGHT) - metric breakdowns and financial figures

For Sight Sciences, Inc. (SGHT), whose expansion relies on the patented Omni system and FDA approvals, this indicator serves as a measure of actual technology penetration into the ophthalmic surgery market. The metric is calculated as the percentage change in revenue over the last twelve months relative to the same period last year, excluding seasonality and short-term market noise. By analyzing the TTM year-over-year product sales volume dynamics, an investor determines whether the company's clinical advantage is transforming into sustainable organic sales growth.